Charlie Strange to Pulmonary Disease, Chronic Obstructive
This is a "connection" page, showing publications Charlie Strange has written about Pulmonary Disease, Chronic Obstructive.
Connection Strength
9.534
-
Feasibility of RESP-FIT: Technology-Enhanced Self-Management Intervention for Adults with COPD. Int J Chron Obstruct Pulmon Dis. 2021; 16:3263-3273.
Score: 0.630
-
Alpha-1 Antitrypsin Deficiency Associated COPD. Clin Chest Med. 2020 09; 41(3):339-345.
Score: 0.578
-
Prevalence of self-reported sleep problems amongst adults with obstructive airway disease in the NHANES cohort in the United States. Sleep Breath. 2020 Sep; 24(3):985-993.
Score: 0.540
-
Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:1377-1388.
Score: 0.532
-
Evaluating fluticasone furoate + vilanterol for the treatment of chronic obstructive pulmonary disease (COPD). Expert Opin Pharmacother. 2019 Jun; 20(9):1075-1085.
Score: 0.525
-
Sequencing Alpha-1 MZ Individuals Shows Frequent Biallelic Mutations. Pulm Med. 2018; 2018:2836389.
Score: 0.503
-
Anti-Proteases and Alpha-1 Antitrypsin Augmentation Therapy. Respir Care. 2018 Jun; 63(6):690-698.
Score: 0.494
-
Mortality in Asthma-Chronic Obstructive Pulmonary Disease Overlap in the United States. South Med J. 2018 05; 111(5):293-298.
Score: 0.491
-
A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD. Expert Opin Pharmacother. 2017 Dec; 18(17):1833-1843.
Score: 0.476
-
COPD in individuals with the PiMZ alpha-1 antitrypsin genotype. Eur Respir Rev. 2017 Dec 31; 26(146).
Score: 0.474
-
Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy. Int J Chron Obstruct Pulmon Dis. 2017; 12:135-140.
Score: 0.448
-
Characteristics and Prevalence of Asthma/Chronic Obstructive Pulmonary Disease Overlap in the United States. Ann Am Thorac Soc. 2016 06; 13(6):803-10.
Score: 0.430
-
Gender and asthma-chronic obstructive pulmonary disease overlap syndrome. J Asthma. 2016 09; 53(7):720-31.
Score: 0.426
-
Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis Study. Alpha-1 Protocol. Ann Am Thorac Soc. 2015 Oct; 12(10):1551-60.
Score: 0.411
-
Treatment of Alpha-1 Antitrypsin Deficiency. Semin Respir Crit Care Med. 2015 Aug; 36(4):470-7.
Score: 0.406
-
Smoking duration, respiratory symptoms, and COPD in adults aged =45 years with a smoking history. Int J Chron Obstruct Pulmon Dis. 2015; 10:1409-16.
Score: 0.405
-
Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2015 Feb; 16(3):427-34.
Score: 0.392
-
Airway disease in alpha-1 antitrypsin deficiency. COPD. 2013 Mar; 10 Suppl 1:68-73.
Score: 0.343
-
Proactive Electronic Visits for Smoking Cessation and Chronic Obstructive Pulmonary Disease Screening in Primary Care: Randomized Controlled Trial of Feasibility, Acceptability, and Efficacy. J Med Internet Res. 2022 08 30; 24(8):e38663.
Score: 0.166
-
Reply: Asthma/COPD Overlap Syndrome and Medicare 30-Day Readmissions. Ann Am Thorac Soc. 2016 07; 13(7):1192.
Score: 0.108
-
Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment. J Manag Care Spec Pharm. 2016 Mar; 22(3):293-304.
Score: 0.106
-
Patterns of Emphysema Heterogeneity. Respiration. 2015; 90(5):402-11.
Score: 0.103
-
Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments. Int J Chron Obstruct Pulmon Dis. 2015; 10:2055-66.
Score: 0.103
-
Targeting Persons With or At High Risk for Chronic Obstructive Pulmonary Disease by State-based Surveillance. COPD. 2015; 12(6):680-9.
Score: 0.102
-
Body mass index, respiratory conditions, asthma, and chronic obstructive pulmonary disease. Respir Med. 2015 Jul; 109(7):851-9.
Score: 0.100
-
The United States Alpha-1 Foundation Research Registry: Genesis, Impact and Future. COPD. 2015 May; 12 Suppl 1:42-5.
Score: 0.100
-
Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study. Respir Res. 2015 Apr 23; 16:52.
Score: 0.100
-
Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med. 2003 Jun 17; 138(12):969-73.
Score: 0.044